eri-1 Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
eri-1 antibody; T07A9.53'-5' exonuclease eri-1 antibody; EC 3.1.-.- antibody; Enhanced RNAi protein antibody
Target Names
eri-1
Uniprot No.

Target Background

Function
ERI-1 is an RNA exonuclease that functions as a negative regulator of RNA interference (RNAi). It is believed to exert its regulatory effect by degrading the 3'-overhangs of short interfering RNAs (siRNAs). ERI-1 is a component of the ERI/DICER complex, which is involved in processing amplified double-stranded RNA (dsRNA) intermediates during small-RNA-mediated gene silencing or RNA interference (RNAi) (Probable).
Gene References Into Functions
  1. In the absence of eri-1, reserpine-mediated lifespan extension (RMLE) is shortened. In the dop-3 loss-of-function background, the absence of eri-1 completely abolishes RMLE. This suggests that dop-3 and eri-1 operate in independent, parallel pathways for RMLE, and these two pathways are essential and sufficient for the longevity enhancement induced by reserpine in C. elegans. PMID: 27966489
  2. Research findings have identified novel components of the endo RNAi machinery, demonstrated differential requirements for the Eri factors in the sperm-producing germline, and begun to delineate the functional requirement for the ERI/DICER complex in sperm development. PMID: 19797044
  3. Following exposure to dsRNA or siRNAs, animals with eri-1 mutations accumulate higher levels of siRNAs compared to wild-type animals. This indicates that eri-1 acts as a negative regulator, potentially modulating the duration, cell-type specificity, or endogenous functions of RNA interference. PMID: 14961122
  4. Feeding unc-13 & eri-1 strains with dsRNA corresponding to a neuronally expressed GFP reporter resulted in a reduction of GFP in double mutants compared to GFP expression in eri-1 mutants, suggesting that UNC-13 functions in conjunction with ERI-1 in RNAi. PMID: 17276405
  5. In C. elegans, two protein isoforms of ERI-1 are localized to the cytoplasm, each with distinct functions in ribosomal RNA processing and negative regulation of RNA interference. PMID: 18438419

Show More

Hide All

Database Links

KEGG: cel:CELE_T07A9.5

STRING: 6239.T07A9.5b

UniGene: Cel.12380

Subcellular Location
Cytoplasm.
Tissue Specificity
Expressed in the somatic developing gonads and in a subset of neurons. In adults, it is specifically expressed in neurons and in spermatheca.

Q&A

What is ERI-1 and what cellular functions does it perform?

ERI-1 is an evolutionarily conserved 3′–5′ exoribonuclease of the DEDDh superfamily of RNase T exonucleases . It contains one exonuclease domain and one SAP domain, with the latter being necessary for binding to the stem-loop structure of histone mRNAs . ERI-1 performs several critical cellular functions:

  • Processing the 3′ end of 5.8S ribosomal RNA in diverse organisms including Caenorhabiditis elegans and Schizosaccharomyces pombe

  • Binding to and degrading histone mRNAs, playing an essential role in their turnover after replication

  • Regulating microRNA homeostasis in lymphocytes, with ERI-1 deficiency resulting in global, sequence-independent increases in miRNA abundance

  • Negatively regulating RNA interference in C. elegans and S. pombe

The multi-functional nature of ERI-1 places it at the crossroads of multiple RNA processing pathways, suggesting potential crosstalk between these different cellular processes.

How does ERI-1 expression impact immune cell development?

ERI-1 plays a critical role in immune cell development, particularly in Natural Killer (NK) cells. Studies with ERI-1-deficient (Eri1−/−) mice have revealed:

  • A 50% reduction in NK cell frequency and absolute numbers in the spleen compared to wild-type siblings

  • Significant reductions in NK cell populations in the liver and bone marrow

  • Delayed acquisition of Ly49 receptors in the bone marrow and selective reduction in Ly49D and Ly49H activating receptors in peripheral NK cells

  • Higher frequencies of immature cell markers (CD27 and NKG2A/C/E) and fewer mature markers (CD49b and CD11b) in Eri1−/− NK cells

These findings suggest ERI-1 regulates critical developmental checkpoints in NK cell maturation through its effects on microRNA homeostasis, making it an important target for immunological research.

What applications are recommended for ERI-1 antibodies in research?

Based on validated protocols, ERI-1 antibodies can be effectively utilized in multiple experimental applications:

ApplicationRecommended DilutionValidated Positive Controls
Western Blotting1:500-1:2000K-562 cells, HepG2 cells, HL-60 cells
Immunohistochemistry1:50-1:500Human liver cancer tissue, human testis tissue
Immunofluorescence/Immunocytochemistry1:10-1:100HepG2 cells
ELISAValidated, dilution not specifiedNot specified

For immunohistochemistry applications, antigen retrieval with TE buffer pH 9.0 is suggested, though citrate buffer pH 6.0 may also be used . The expected molecular weight of ERI-1 is approximately 40 kDa, but it is typically observed at 46 kDa on western blots .

How can ERI-1 antibodies be used to study microRNA regulation pathways?

ERI-1 antibodies provide valuable tools for investigating microRNA regulation mechanisms:

  • Immunoprecipitation experiments can isolate ERI-1-bound microRNAs to identify specific miRNA targets regulated by ERI-1

  • Western blotting with ERI-1 antibodies allows quantification of expression levels that can be correlated with miRNA abundance in different cell types or experimental conditions

  • Comparing miRNA profiles between wild-type and Eri1−/− cells using microarray analysis has revealed that ERI-1 deficiency causes a global, sequence-independent increase in miRNA abundance in both NK and T cells

  • Localizing ERI-1 within cellular compartments via immunofluorescence can help determine where miRNA processing occurs

Research has demonstrated that ectopic ERI-1 expression can rescue defective miRNA expression in mature Eri1−/− T cells, confirming its direct role in miRNA homeostasis .

How do researchers distinguish between different ERI-1 isoforms?

In C. elegans, two protein isoforms of ERI-1 (ERI-1a and ERI-1b) are localized to the cytoplasm and have distinct functional properties :

  • Both isoforms can mediate 5.8S rRNA processing when expressed in eri-1 null mutants

  • Only ERI-1b efficiently rescues the enhanced RNAi phenotype observed in eri-1 mutants

  • ERI-1b's extended C-terminal domain may facilitate interaction with DCR-1 (Dicer), which is important for its activity in endogenous siRNA biogenesis and inhibition of exogenous RNAi

Researchers can distinguish between these isoforms using:

  • Isoform-specific antibodies targeting unique C-terminal regions

  • RT-PCR assays to detect specific mRNA splice variants

  • Expression of GFP-tagged isoforms to observe differential subcellular localization patterns

When designing experiments, researchers should consider which isoform is relevant to their pathway of interest and select antibodies that can specifically detect that isoform.

What role does ERI-1 play in antiviral immunity?

ERI-1 is required for effective immune-mediated control of viral infections, particularly mouse cytomegalovirus (MCMV) :

  • Ly49H+ NK cells deficient in ERI-1 fail to expand efficiently during MCMV infection

  • Virus-specific responses are also diminished among Eri1−/− T cells

  • The global increase in miRNA abundance in Eri1−/− lymphocytes likely contributes to these defects in antiviral immunity

These findings suggest that ERI-1-mediated regulation of miRNA homeostasis is critical for proper immune responses to viral infections. Researchers studying antiviral immunity should consider ERI-1 as an important factor affecting both innate and adaptive immune responses.

How can researchers validate ERI-1 antibody specificity?

Ensuring antibody specificity is crucial for generating reliable experimental data. The following validation approaches are recommended:

  • Use positive controls known to express ERI-1 (K-562 cells, HepG2 cells, HL-60 cells for western blotting; human liver cancer tissue for IHC)

  • Include negative controls such as ERI-1 knockdown or knockout samples

  • Perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide

  • Verify reactivity across species if working with non-human models (the antibody described has confirmed specificity for human, mouse, and rat ERI-1)

  • Test for cross-reactivity with other DEDDh family exonucleases

Validation experiments should be performed for each new lot of antibody and whenever changing experimental conditions or cell types.

What are the critical experimental controls when studying ERI-1 function?

When investigating ERI-1 function in RNA processing pathways, several critical controls should be included:

  • Catalytically inactive ERI-1 mutants (H317A and D321A double mutant in C. elegans) that disrupt the protein's exonuclease activity while maintaining protein expression

  • Wild-type and mutant ERI-1 transgene expression to assess rescue of phenotypes

  • Mixed bone marrow chimeras to evaluate cell-intrinsic versus cell-extrinsic effects of ERI-1 deficiency

  • Time course experiments to distinguish between developmental versus maintenance roles

  • Comparative analysis of different RNA pathways (e.g., miRNA, rRNA processing, histone mRNA) to assess pathway-specific effects

In C. elegans studies, expression of either ERI-1a or ERI-1b rescued 5.8S rRNA processing defects, but only ERI-1b effectively rescued enhanced RNAi phenotypes, highlighting the importance of isoform-specific controls .

What approaches can resolve technical challenges in ERI-1 antibody-based experiments?

Researchers may encounter several technical challenges when working with ERI-1 antibodies:

ChallengeTroubleshooting Approach
High background in western blotsIncrease blocking time, use alternative blocking agents, increase washing steps, optimize antibody dilution
Weak or no signal in immunostainingTest alternative fixation methods, optimize antigen retrieval (TE buffer pH 9.0 recommended), increase antibody concentration
Multiple bands in western blottingVerify against ERI-1 knockout control, use more stringent washing, consider presence of different isoforms or post-translational modifications
Poor immunoprecipitation efficiencyPre-clear lysates thoroughly, optimize antibody-to-bead ratio, consider crosslinking antibodies to beads

When investigating ERI-1's role in small RNA pathways, researchers should be aware that human ERI-1 has a calculated molecular weight of 40 kDa but is observed at 46 kDa on western blots , which may be due to post-translational modifications.

How can researchers design experiments to differentiate between ERI-1's multiple RNA processing functions?

Given ERI-1's involvement in multiple RNA processing pathways, experimental design should carefully isolate specific functions:

  • Compare miRNA profiles in wild-type versus Eri1−/− cells using microRNA microarrays (similar to approaches that identified global increases in miRNA abundance in ERI-1-deficient lymphocytes)

  • Assess 5.8S rRNA processing using RNase H and sequencing analysis to identify 3' extended 5.8S rRNA species (2-8 additional nucleotides were observed in S. pombe eri1Δ mutants)

  • Test both rRNA processing and RNAi phenotypes in the same experimental system to determine whether they can be uncoupled

  • Conduct structure-function studies with domain-specific mutations to determine which regions of ERI-1 are required for each function

  • Express isoform-specific constructs in knockout cells to identify which functions can be rescued by which isoforms

These approaches can help researchers dissect the complex functional repertoire of ERI-1 and understand how its different activities may be coordinated or independently regulated.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.